Clinical Trial Update: Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age [Phase 2]

View source ↗

Summary

This clinical trial update presents results from a Phase II study evaluating a triplet regimen of bendamustine, rituximab, and venetoclax in untreated mantle ce…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Bendamustine (Bendamustine)
• Rituximab (rituximab)
• Venetoclax (venetoclax)

Snippet

Sponsor: PrECOG, LLC. | Conditions: Mantle Cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2024-01-23